|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's range||174.78 - 178.01|
|52-week range||155.72 - 186.69|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||24.79|
|Earnings date||24 Jan 2023|
|Forward dividend & yield||4.52 (2.55%)|
|Ex-dividend date||21 Nov 2022|
|1y target est||183.10|
Johnson & Johnson (JNJ) closed at $178 in the latest trading session, marking a +1.08% move from the prior day.
NEW BRUNSWICK, N.J., November 30, 2022--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Chief Executive Officer, Mr. Joaquin Duato, to assume the additional position of Chairman, effective in January 2023. Mr. Duato succeeds Mr. Alex Gorsky, who will step down from his role as Executive Chairman following a brief transitional period.
(Bloomberg) -- Horizon Therapeutics Plc rose by the most in more than three years after the drug developer disclosed it’s in talks with a trio of potential suitors about a possible sale of the company.Most Read from BloombergScientists Revive 48,500-Year-Old ‘Zombie Virus’ Buried in IceAn Arizona County’s Refusal to Certify Election Results Could Cost GOP a House SeatStock Traders Cheer Powell’s Risk-Friendly Shift: Markets WrapNYC Becomes One Billionaire Family’s Haven From China Property Crash